MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$2.90 USD
-0.03 (-1.02%)
Updated Jun 14, 2024 02:29 PM ET
4-Sell of 5 4
A Value B Growth D Momentum A VGM
Brokerage Reports
MEI Pharma, Inc. [MEIP]
Reports for Purchase
Showing records 81 - 100 ( 141 total )
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Presents Positive Updated Interim Data from Phase II Study of Pracinostat and Vidaza in Elderly Patients Previously Untreated with AML
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
AML Study Enrollment Complete; Expect Strong Showing at ASH
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Improved Patient Reponses and Enrollment Completed in Ph 2 Front-Line AML Study, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
ASH Abstracts Released; Additional Positive AML Data Build Case for Pracinostat, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Nice ASH Abstract and F1Q15 Results; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
ME-344 Expansion Study Gets Going; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Key Upcoming Inflection Points; Adding to Focus List; Target to $22
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Healthcare - Potential Short-term Weakness in AML, but Approaches Are Differentiated
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
FY14 Results; ASH Coming Quickly; Recommend Owning Stock Ahead of It
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Moving Toward Major Data Catalysts; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
LIFE SCIENCES AND HEALTH CARE - 2014 LSMAC Day 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L